Novel inhibitors of carboxypeptidase G2 (CPG2): potential use in antibody-directed enzyme prodrug therapy

J Med Chem. 1999 Mar 25;42(6):951-6. doi: 10.1021/jm990004i.

Abstract

The design and synthesis of potent thiocarbamate inhibitors for carboxypeptidase G2 are described. The best thiocarbamate inhibitor N-(p-methoxybenzenethiocarbonyl)amino-L-glutamic acid 6d, chosen for preliminary investigations of in vitro antibody-directed enzyme prodrug therapy (ADEPT), abrogated the cytotoxicity of a combination of A5B7-carboxypeptidase G2 conjugate and prodrug PGP (N-p-{N,N-bis (2-chloroethyl)amino}phenoxycarbonyl-L-glutamate) toward LS174T cells. This is the first report of a small-molecule enzyme inhibitor proposed for use in conjunction with the ADEPT approach.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aniline Mustard / analogs & derivatives
  • Aniline Mustard / pharmacology
  • Antibodies / pharmacology*
  • Antineoplastic Agents / pharmacology*
  • Chromatography, Thin Layer
  • Enzyme Inhibitors / chemical synthesis*
  • Enzyme Inhibitors / chemistry
  • Enzyme Inhibitors / pharmacology
  • Inhibitory Concentration 50
  • Magnetic Resonance Spectroscopy
  • Prodrugs / pharmacology*
  • Structure-Activity Relationship
  • Tumor Cells, Cultured
  • gamma-Glutamyl Hydrolase / antagonists & inhibitors*
  • gamma-Glutamyl Hydrolase / pharmacology

Substances

  • (4-(N,N-bis(2-chloroethyl)amino)phenoxycarbonyl)glutamic acid
  • Antibodies
  • Antineoplastic Agents
  • Enzyme Inhibitors
  • Prodrugs
  • Aniline Mustard
  • gamma-Glutamyl Hydrolase